Diagnostic and treatment assembly

ABSTRACT

A diagnostic and treatment assembly, configured to diagnose and treat cellular disease. The diagnostic and treatment assembly has a radio wave generator communicatively coupled to a carrier modulator and a radio wave amplifier. An impedance matching system is electrically coupled to the radio wave amplifier. A reflected wave sensor is electrically coupled to the impedance matching system. A radiator applicator is electrically coupled to the reflected wave sensor. A vector impedance analyzer is electrically coupled to the radio wave amplifier. An information collector data network is electrically coupled to the vector impedance analyzer. A data logger is communicatively coupled to the carrier modulator, the vector impedance analyzer, and the reflected wave sensor. The diagnostic and treatment assembly operates in a low-power mode to diagnose a cellular disease and in a high-power mode to treat the cellular disease.

COPYRIGHT STATEMENT

A portion of the disclosure of this patent document contains materialthat is subject to copyright protection. The copyright owner has noobjection to the facsimile reproduction by anyone of the patent documentor the patent disclosure as it appears in the Patent and TrademarkOffice patent file or records, but otherwise reserves all copyrightrights whatsoever.

Trademarks used in the disclosure of the invention and the applicantsmake no claim to any trademarks referenced.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority from U.S. patent application Ser. No.17/245,817, filed Apr. 30, 2021, titled DIAGNOSTIC AND TREATMENTASSEMBLY and U.S. patent application Ser. No. 16/882,156, filed May 22,2020, titled DIAGNOSTIC AND TREATMENT ASSEMBLY which are herebyincorporated by reference herein for all purposes.

BACKGROUND OF THE INVENTION 1) Field of the Invention

The invention relates to the field of treatment and diagnostic medicaldevices, and, more particularly to a diagnostic medical device. Morespecifically, it relates to a detection and treatment instrument, andmore particularly, to an instrument for detecting and treating cellsusing radio frequency waves.

Prior to embodiments of the disclosed invention, detecting and treatingcellular illness without harming other healthy cells was extensivelytime consuming. Some other endeavors in this field include U.S. Pat. No.9,320,911 issued to Szasz; U.S. Patent Application Pre-grant publication2008/0319437 filed by Turner; and U.S. Patent Application Pre-grantpublication 2008/0200803 filed by Kwon. Embodiments of the disclosedinvention solve this problem.

2) Description of Related Art

Currently, the state of the art includes systems for detecting andtreating cellular illness without harming other healthy cells wasextensively time consuming.

In particular detecting and treating cellular illness without harmingother healthy cells is difficult. For example, a mammography method isused to detect mammary cancer. However, the detection of mammary cancerusing that method depends on the age of patients or structures ofmammary tissues. It is easy to detect a problem in the mammary tissuesusing the mammary method, but it is dangerous to judge the abnormallesion as cancer. Therefore, the same detection test should be repeatedor other tests, such as ultrasonic diagnosis or biopsy, should be used.

Radiofrequency (RF) radiation, which includes radio waves andmicrowaves, is at the low-energy end of the electromagnetic spectrum. RFradiation has lower energy than some other types of non-ionizingradiation, like visible light and infrared, but it has higher energythan extremely low-frequency (ELF) radiation.

An example of the effectiveness of the use of radio frequency waves iswhen the radio waves are directed to cancer cells. Cancer cells have asize larger than a predetermined size and have a morphologicalvariation. A biopsy can cause de-formation of cell shapes and hasdifficulty in judging metastasis of cancer cells. The above mentionedmethods are the only methods currently used for detecting cancer, andthus an additional method for the detection and treatment of cancershould be considered.

However, the current devices do not provide a method to identify adisease state and treat the disease state.

Therefore, what is needed in the art is a device which can rapidlyidentify the disease state and can be optionally configured to treat thediseased cells if needed.

BRIEF SUMMARY OF THE INVENTION

The instant invention in one form is directed to increase longevity andreduce pain through technology and innovation. The technology of theinstant invention is designed to help address some of the hardestproblems faced by medicine which is a faster, cheaper, and more accuratediagnosis and treatment of diseases.

An advantage of the present invention is the ability to utilize thetechnology to diagnose diseases by detecting the presence of biologicalstructures, like viruses, bacteria, and cancerous cells, and to treatdiseases by inactivating such structures without harming healthyneighboring cells or biological structures.

A diagnostic and treatment assembly, configured to diagnose and treatcellular disease. The diagnostic and treatment assembly has a radio wavegenerator communicatively coupled to a carrier modulator and a radiowave amplifier. An impedance matching system is electrically coupled tothe radio wave amplifier. A reflected wave sensor is electricallycoupled to the impedance matching system. A radiator applicator iselectrically coupled to the reflected wave sensor. A vector impedanceanalyzer is electrically coupled to the radio wave amplifier. Aninformation collector data network is electrically coupled to the vectorimpedance analyzer. A data logger is communicatively coupled to thecarrier modulator, the vector impedance analyzer, and the reflected wavesensor. The diagnostic and treatment assembly operates in a low-powermode to diagnose a cellular disease and in a high-power mode to treatthe cellular disease.

In some embodiments, an electronic system is communicatively coupled tothe data logger and is programmed with instructions to direct theradiator applicator to administer at least five but less than onehundred watts of power to a human in need of such diagnosis. Theelectronic system can be further programmed to analyze the relationshipbetween energy sent and reflected to a body region under analysis withthe data logger. The electronic system can be further programmed tomeasure phase and quadrature deviations between the wave originallygenerated by the equipment and the one that passed through the bodyunder analysis with the data logger. The electronic system can befurther programmed to determine cellular disease exists when the phaseand quadrature deviations exceed ten percent.

In some embodiments, an electronic system is communicatively coupled tothe data logger and is programmed with instructions to direct theradiator applicator to administer at least one hundred watts but lessthan one thousand watts of power to a human in need of such treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

A further understanding of the nature and advantages of particularembodiments may be realized by reference to the remaining portions ofthe specification and the drawings, in which like reference numerals areused to refer to similar components. When reference is made to areference numeral without specification to an existing sub-label, it isintended to refer to all such multiple similar components.

FIG. 1 shows a pictorial schematic diagram of one embodiment of thepresent invention;

FIG. 2 shows a schematic of diagram of one embodiment of the presentinvention;

FIG. 3 shows a schematic of diagram of one embodiment of the presentinvention;

FIG. 4 is a simple depiction of the sample and the transmitter andreceiver of the instant invention;

FIG. 5 is flow chart of algorithm to find the best channel;

FIG. 6 shows a table showing the count of live cells per Elisa plate inthe control sample;

FIG. 7 shows a table of the count of live cells per Elisa well in thesample containing cancer cells;

FIG. 8 is showing a table of the percentage of surviving cancer cellscompared to control sample;

FIG. 9 is a model of the COVID-19 virus;

FIG. 10 shows the assembled view of the instant invention;

FIG. 11 shows an exploded view of the instant invention;

FIG. 12 shows a flow chart of the trial process;

FIG. 13 shows a setup containing transmitter, and Elisa plates insidethe dipole antenna;

FIG. 14 shows an Elisa plate inside the antenna—the right side is thenegative control sample;

FIG. 15 shows an irradiation sample and the formation of bubbles in thecontrol in Elisa's plate samples;

FIG. 16 shows an irradiation sample and the formation of bubbles incancerous in Elisa's plate samples;

FIG. 17 shows results for the complete Covid-19 test.

Corresponding reference characters indicate corresponding partsthroughout the several views. The exemplifications set out hereinillustrate embodiments of the invention and such exemplifications arenot to be construed as limiting the scope of the invention in anymanner.

DETAILED DESCRIPTION

While various aspects and features of certain embodiments have beensummarized above, the following detailed description illustrates a fewexemplary embodiments in further detail to enable one skilled in the artto practice such embodiments. The described examples are provided forillustrative purposes and are not intended to limit the scope of theinvention.

In the following description, for the purposes of explanation, numerousspecific details are set forth in order to provide a thoroughunderstanding of the described embodiments. It will be apparent to oneskilled in the art, however, that other embodiments of the presentinvention may be practiced without some of these specific details.Several embodiments are described herein, and while various features areascribed to different embodiments, it should be appreciated that thefeatures described with respect to one embodiment may be incorporatedwith other embodiments as well. By the same token, however, no singlefeature or features of any described embodiment should be consideredessential to every embodiment of the invention, as other embodiments ofthe invention may omit such features.

In this application the use of the singular includes the plural unlessspecifically stated otherwise and use of the terms “and” and “or” isequivalent to “and/or,” also referred to as “non-exclusive or” unlessotherwise indicated. Moreover, the use of the term “including,” as wellas other forms, such as “includes” and “included,” should be considerednon-exclusive. Also, terms such as “element” or “component” encompassboth elements and components including one unit and elements andcomponents that include more than one unit, unless specifically statedotherwise.

Lastly, the terms “or” and “and/or” as used herein are to be interpretedas inclusive or meaning any one or any combination. Therefore, “A, B orC” or “A, B and/or C” mean “any of the following: A; B; C; A and B; Aand C; B and C; A, B and C.” An exception to this definition will occuronly when a combination of elements, functions, steps or acts are insome way inherently mutually exclusive.

As this invention is susceptible to embodiments of many different forms,it is intended that the present disclosure be considered as an exampleof the principles of the invention and not intended to limit theinvention to the specific embodiments shown and described.

The terms virus, cancer cell, cells are used interchangeably to meancells that can be treated or diagnosed by the instant invention.

As used in this application, the term “a” or “an” means “at least one”or “one or more.”

As used in this application, the term “about” or “approximately” refersto a range of values within plus or minus 10% of the specified number.

As used in this application, the term “substantially” means that theactual value is within about 10% of the actual desired value,particularly within about 5% of the actual desired value and especiallywithin about 1% of the actual desired value of any variable, element orlimit set forth herein.

The prior art does not provide for a system that is capable ofdiagnosing a condition or a viral infection using radio waves. The priorart includes U.S. Pat. No. 9,320,911, Issue Date: Apr. 26, 2016; U.S.Patent Application 20080319437, Publication Date: Dec. 25, 2008; andU.S. Patent Application 20080200803, Publication Date: Aug. 21, 2008 thecontents of which are incorporated by reference in their entirety.

By way of example, and referring to FIGS. 1-2, one embodiment of adiagnostic and treatment assembly 10 further comprises a radio wavegenerator 12 communicatively coupled to a carrier modulator 14 and ametal bulkhead 16. The radio wave generator 12 is electrically coupledto a radio wave amplifier 18 with a first transmission line 20. Animpedance matching system 24 is electrically coupled to the radio waveamplifier 18 with a second transmission line 26. A reflected wave sensor28 is electrically coupled to the impedance matching system 24 with athird transmission line 30. A radiator applicator 32 is electricallycoupled to the reflected wave sensor 28 with a fourth transmission line36.

A vector impedance analyzer 38 is electrically coupled to the radio waveamplifier 18 with a fifth transmission line 40. An information collectordata network 42 is electrically coupled to the vector impedance analyzer38 with a sixth transmission line 44.

A data logger 46 is communicatively coupled to the carrier modulator 14,the vector impedance analyzer 38, and the reflected wave sensor 28. Thedata logger 46 is communicatively coupled to an electronic system 200.

FIG. 3 conceptually illustrates the electronic system 200 with whichsome embodiments of the invention are implemented. The electronic system200 may be a computer, phone, PDA, or any other sort of electronicdevice. An electronic system includes various types of computer readablemedia and interfaces for various other types of computer readable media.Electronic system 200 includes a bus 205, processing unit(s) 210, asystem memory 215, a read-only-memory 220, a permanent storage device225, input devices 230, output devices 235, and a network 240.

The bus 205 collectively represents all system, peripheral, and chipsetbuses that communicatively connect the numerous internal devices of theelectronic system 200. For instance, the bus 205 communicativelyconnects the processing unit(s) 210 with the read-only-memory 220, thesystem memory 215, and the permanent storage device 225.

From these various memory units, the processing unit(s) 210 retrievesinstructions to execute and data to process in order to execute theprocesses of the invention. The processing unit(s) may be a singleprocessor or a multi-core processor in different embodiments.

The read-only-memory (ROM) 220 stores static data and instructions thatare needed by the processing unit(s) 210 and other modules of theelectronic system. The permanent storage device 225, on the other hand,is a read-and-write memory device. This device is a non-volatile memoryunit that stores instructions and data even when the electronic system200 is off. Some embodiments of the invention use a mass-storage device(such as a magnetic or optical disk and its' corresponding disk drive)as the permanent storage device 225.

Other embodiments use a removable storage device (such as a floppy diskor a flash drive) as the permanent storage device 225. Like thepermanent storage device 225, the system memory 215 is a read-and-writememory device. However, unlike storage device 225, the system memory 215is a volatile read-and-write memory, such as a random access memory. Thesystem memory 215 stores some of the instructions and data that theprocessor needs at runtime.

In some embodiments, the invention's processes are stored in the systemmemory 215, the permanent storage device 225, and/or the read-only 220.For example, the various memory units include instructions forprocessing appearance alterations of displayable characters inaccordance with some embodiments. From these various memory units, theprocessing unit(s) 210 retrieves instructions to execute and data toprocess in order to execute the processes of some embodiments.

The bus 205 also connects to the input and output devices 230 and 235.The input devices enable the person to communicate information andselect commands to the electronic system. The input devices 230 includealphanumeric keyboards and pointing devices (also called “cursor controldevices”). The output devices 235 display images generated by theelectronic system 200. The output devices 235 include printers anddisplay devices, such as cathode ray tubes (CRT) or liquid crystaldisplays (LCD). Some embodiments include devices such as a touchscreenthat functions as both input and output devices.

Finally, as shown in FIG. 3, bus 205 also couples electronic system 200to a network 240 through a network adapter (not shown). In this manner,the computer can be part of a network of computers (such as a local areanetwork (“LAN”), a wide area network (“WAN”), or an intranet), or anetwork of networks (such as the Internet). Any or all components ofelectronic system 200 may be used in conjunction with the invention.

These functions described above can be implemented in digital electroniccircuitry, in computer software, firmware or hardware. The techniquescan be implemented using one or more computer program products.Programmable processors and computers can be packaged or included inmobile devices. The processes may be performed by one or moreprogrammable processors and by one or more sets of programmable logiccircuitry. General and special purpose computing and storage devices canbe interconnected through communication networks.

Some embodiments include electronic components, such as microprocessors,storage and memory that store computer program instructions in amachine-readable or computer-readable medium (alternatively referred toas computer-readable storage media, machine-readable media, ormachine-readable storage media). Some examples of such computer-readablemedia include RAM, ROM, read-only compact discs (CD-ROM), recordablecompact discs (CD-R), rewritable compact discs (CD-RW), read-onlydigital versatile discs (e.g., DVD-ROM, dual-layer DVD-ROM), a varietyof recordable/rewritable DVDs (e.g., DVD-RAM, DVD-RW, DVD+RW, etc.),flash memory (e.g., SD cards, mini-SD cards, micro-SD cards, etc.),magnetic and/or solid state hard drives, read-only and recordableBlu-Ray® discs, ultra-density optical discs, any other optical ormagnetic media, and floppy disks. The computer-readable media may storea computer program that is executable by at least one processing unitand includes sets of instructions for performing various operations.Examples of computer programs or computer code include machine code,such as is produced by a compiler, and files including higher-level codethat are executed by a computer, an electronic component, or amicroprocessor using an interpreter.

The diagnostic and treatment assembly 10 has a diagnostic mode ofoperation and a treatment mode of operation.

The diagnostic mode generally lasts no longer than one hour. During thistime, the radiator applicator 32 generates wave power of at least 5watts but no more than 100 W. Then, the data logger 46 analyzes therelationship between energy sent and reflected to the body region underanalysis. After that, the data logger 46 measures phase and quadraturedeviations between the wave originally generated by the equipment andthe one that passed through the body under analysis. Finally, if thedeviations are greater than 10%, the electronic system 200 indicatescell disease, such as cancer, due to the resonance with the specificcell density. The location of the cell disease is called a treatmentarea.

In the treatment mode, the radiator applicator generates wave power ofat least 100 watts but no more than 1000 watts directed to the treatmentarea. In the presence of this wave, the Krebs cycle of diseased cells isinterrupted, which, after a period of several hours, leads to death ofthe diseased cells.

As described, the instant invention is a device that uses a method todifferentiate and detect biological nanostructures and to treatbiological diseases. The instant invention is based on the induction ofhigh frequency magnetic resonance in the sample, in the ultrahighfrequency (UHF) and super high frequency (SHF) bands. This processgenerates two pieces of information for each frequency the sample isexposed to:

The sample absorption rate; and

The phase difference between the signal transmitted and received, inorder to measure the magnetic reluctance.

Referring to FIG. 4 which shows a simplified drawing of the instantinvention you can see a test tube 400 with a biological sample 401 init, as well as a transmitter 410 and a receiver 420. The sample 401 iscrossed by radio waves generated by the transmitter 410 and the receiver420 will capture the energy that has not been absorbed by the sample401. The difference between the energy transmitted and the energyreceived results in the energy absorbed by the sample 401.

Once the absorption for a frequency range in a variable magnetic fieldis detected, the alignment times (at the moment of transmission) andmisalignment of the dipoles (moment when the transmission of the RadioFrequency (R.F.) signal is interrupted) are verified. The differencebetween the alignment times result in the phase of the signal thatcrossed the sample. These time intervals, associated with the overallenergy absorption of the sample, are tested at various frequencies inthe UHF and SHF range, generating a spectral profile of what iscontained in the sample. Knowing that each sample, solution, or materialhas a unique spectral profile signature, the technology is capable ofdifferentiating these various signatures.

The instant invention measures the absorption of the sample 401. When inthe presence of a variable electromagnetic field, the sample assumesalternating behaviors of magnetization and demagnetization states. Atthe time of magnetization, a component part of the circuit, which isitem 16 of the components list related to FIG. 11 is responsible forreading how much energy has been absorbed by the sample.

The instant invention then measures the phase of the signal that crossesthe sample.

When the field ceases, the sample is demagnetized and its magneticdipoles misalign. At that moment, a voltage is generated by thisdemagnetization and is picked up by the antenna receiver and interpretedby the component item 16 of the components list related to FIG. 11. Thisdevice measures the phase, which is the time of misalignment of theparticles until the end of the demagnetization.

The instant invention then measures the magnetic reluctance also knownas reluctance, magnetic resistance, or a magnetic insulator which isdefined as the opposition offered by a magnetic circuit to theproduction of magnetic flux.

The instant invention then measures the range of frequencies also knownas the spectrum of the sample. The instant invention needs to understandthe size of the structures which are being analyzed so that the instantinvention knows the frequency that the structure resonates with.

Once you know the size of the structure the instant invention is able tocalculate the fundamental frequency to resonate with the structure.

To determine the size and frequency required research to find the sizesof the structures that are relevant to our determining diagnosticsignatures for carious disseated cells. The research created thefollowing data:

a. Virus—200 to 500 nm—“Virus frequencies have been measured for manyyears by engineer André Simoneton and it shows that all viruses vibrateat low frequencies, below 5000 angstroms (1angstrom=0.0001 μm).”

b. BCL-2 Proteins (Relevant for cancer detection and treatment)—3 to 6nm—“A simple rule of thumb for thinking about typical soluble proteinslike the Rubisco monomer is that they are 3-6 nm in diameter.”

-   -   c. Mitochondria (Relevant for cancer detection and        treatment)—0.5 to 1 μm—“Mitochondria are organelles typically        ranging in size from 0.5 micrometer to 1 micrometer in length,        found in the cytoplasm of eukaryotic cells.”    -   d. Bacteria—0.2 to 2 μm—“In general, bacteria are between 0.2        and 2.0 μm—the average size of most bacteria.”

Knowing the sizes of the structures one can see that the smalleststructure is the virus, around 200 nm as opposed to the largeststructure, around 2 μm. Therefore, this gives a range of frequenciesfrom 1500 Terahertz (THz) to 150 THz.

The electronics capable of generating signals in the range of hundredsof THz is currently restricted in the laboratory environment and isstill being studied. Therefore, to overcome this problem the inventionuses a harmonic resonant of the fundamental frequencies. “Harmonics arethe sinusoidal voltage or current that is an integer (whole number) at amultiple of the fundamental frequency at which the supply system isdesigned to operate.”

Therefore, for each target to be to identify, one must calculate theharmonic range for that structure and set up the hardware to run aspectral analysis for the samples in the range calculated. As explainedthe spectral analysis will give two outputs for each frequency(absorption and phase). This data, complemented with the control sampletest result serves as the input for the learning stage.

The Learning Stage of the development. When given a specific samplelet's say a virus, the instant invention processes it and returns thevalues of absorption of frequency and electromagnetic phase regarding apredefined channel. Next the process is to evaluate a range of 250different channel values in order to better discriminate the attributes.From these outputs, it is possible to assess which channel betterseparates the samples into positive and negative groups. The channelselection is performed as follows: the data is grouped by thediagnostics, then the system calculates the difference of absorption offrequency between both groups. The channel that presents the greatestdifference (i.e., greatest separability between positives and negatives)for the sample (the virus) is selected. The overall process of thisapproach is illustrated in the FIG. 5 which illustrates the presence ofthe virus detection.

Subsequently, the instant invention builds a dataset containing theattributes regarding the best channel. From the dataset, the instantinvention is able to employ a machine learning algorithm to induce amodel that predicts the diagnostic of samples analyzed by the instantinvention. More specifically, the instant invention has trained a randomforest to accomplish it, although the instant invention has assesseddifferent algorithms, such as logit, decision trees, support-vectormachine (SVM), etc. This allows the instant invention to use a smallamount of data.

The technology of the instant invention is a platform to improve theprocess of diagnosing and treating multiple diseases caused by virusesas but not limited to Influenza, Coronavirus, Sars-Cov-2, HIV, Herpes,Dengue, Zika, etc., bacteria such as but not limited to Strep throat, E.Coli, Salmonella, etc., or tumorous cells such as but not limited tobreast cancer, skin cancer, lung cancer, prostate cancer, etc.

The process explained has been applied to the initial studies for humanmammary tumorous cells and for Covid19, demonstrating that the sameprocess can be applied to multiple diseases with results which arebetter or equal to the current Gold standard (PCR test-Polymerase chainreaction) currently used to identify the disease.

Turning the attention to the test for breast cancer. The methodologyused by the instant invention for cancer diagnosis and treatment isdeveloped on top of a modulated electro-hyperthermia methodology. Thismakes use of an already known principle for cancer treatment, modulatedelectro hyperthermia or mEHT. In short, it is about radiating radiowaves in the 13 MHz band with high power causing heating of tumorcells—and other healthy cells around them—causing their death. Modulatedelectro-hyperthermia (mEHT) can induce an abscopal effect and therebyenhance the antitumor effects of immunotherapy.

The evaluation focused on understanding the phenomenon in order tocounteract the side effects of the heating and death of healthy cells.Initially, in-vitro tests were performed on human mammary tumorous cellsin order to determine the minimum potency per area that caused theeffect and it was noticed that it was possible to cause the same effect(cell death) with a much lower power, which did not cause heating of thecells, by adding another frequency range, in the kilohertz (KHz) range,modulating the main wave of 13 Megahertz(MHz) in a single side band(pulsed wave).

The development of this technique used the same method of analysisexplained previously where a wide test of modulations is applied.

The investigators noticed that the BCL-2 protein is an indication of thetumorous cells presence and its average size is 5 nm. That gives afundamental frequency of 59 Petahertz (PHz). Calculating ‘n’=4600000they obtained 13 MHz as one of the harmonic frequencies of the BCL-2fundamental frequency.

Since 13 MHz is the frequency used in traditional mEHT (with high powersand without selectivity), the researchers calculated the second harmonicat the top of the fundamental, resulting in a frequency of 2.8 KHz,allowing the use of low potencies and a high degree of selectivity forthe diagnosis and treatment of cancer.

Modulated electro hyperthermia or mEHT innovation with pulsed waves forcancer treatment. As described, mEHT alone is not able to prevent damageto the healthy cells that are proximal to the cancer cells. Theinvestigators undertook laboratory tests to determine a way to innovatethe mEHT process by making it selective, affecting only cancer cells.

The first step was to experimentally determine the power limit at 13 MHzapplied with the 2.8 KHz pulses that maximized the impact on cancercells because this modulation is a harmonic of the BCL-2 protein. Thisprotein is widely present in tumor cells of several cancers and the 2.8KHz modulation was adopted in order to maximize the impact on tumorcells. The sample tumor cells were placed in Elisa plates. To maximizethe impact on tumor cells, a test system containing a transmitter at thefrequency of 13 MHz was modulated, modulating this wave at 2.8 KHz and adipole antenna with a special arrangement to cause a power gradient inthe wells of the Elisa plates. Setup containing transmitter, and Elisaplates inside the dipole antenna FIG. 13 and Elisa plates inside theantenna—the right side is the negative control sample FIG. 14.

The tests were performed using healthy human mammary cells (L929) forcontrol and L929 with laboratory-induced cancer. The cells were alwayscultured together—to guarantee equivalence in their lifetime—and threereplicates were cultured for a wide analysis, which would guaranteerepeatability in the results.

After the tests with an irradiation duration of 3 hours each, it wasnoticed that the cancer cells had a much greater impact compared to thecontrol sample. In the figure to the left, the formation of bubbles canbe seen in the control samples FIG. 15 and in the cancerous samples inElisa's plate FIG. 16.

After each irradiation, a cell survival count is performed, with theproper mapping of the minimum useful power that would cause the impact.This allowed comparison between the mEHT and modulated mEHTtechnologies.

FIG. 6 worksheet shows the amount of healthy L929 cells in each well ofthe Elisa plate that has the control samples. All the numbers aremultiplied by 2.10×10⁴.

FIG. 7 worksheet shows the amount of L929 cells with cancer in each wellof the Elisa's plate. All the numbers are multiplied by 2.10×10⁴.

Also, there are three regions:

-   -   1. The first one, called LOW=0.01 W, is the low power area (that        received 0.01 W).    -   2. The second region, called MID=0.1 W, is the mid power area        (that received 0.1 W).    -   3. The third one, called MAX>1 W, is the high power area (that        received 1 W). This last power is considered the initial power        to cancer treatments based on mEHT.

At the end of the tests, a considerable difference in the cancerouscell's death was observed in the areas of medium and high power. It wasalso found that using powers above the “MID POWER” zone did not add moreresults. Proving that low potencies, less than 1 W, kill just thecancerous cells, keeping the healthy cells alive because there is noheating.

The fact that it does not use high potencies (above 1 W) allows healthycells to remain alive.

FIG. 8 worksheet shows the percentage of surviving cancer cells comparedto control sample.

Once the set of modulations and frequencies that caused the cell deathof the tumor cells, we experimentally investigated the cause of thedeath. We discovered that the tumor cells died by the Krebs cycleinterruption. This interruption of the cycle was caused by theinteraction of the chosen frequencies in the experiment with BCL-2protein. This protein is directly related to the glucose flow to theinside of tumor cells. The explanation and details can be seen in thefollowing reference Nature.com, Cell Research Published Dec. 8, 2017,Mitochondrial metabolism and cancer by Paolo Ettore Porporato, NicolettaFiligheddu, José Manuel Bravo-San Pedro, Guido Kroemer and LorenzoGalluzzi. https://www.nature.com/articles/cr2017155.

Therefore, it is clear that the instant invention has two modes ofoperation: diagnosis and treatment.

In the diagnostic mode, exactly the same technique is applied, where theinstant invention observes the profile of the magnetic echoes caused bythe magnetization and demagnetization of the analyzed sample to confirmthe disease.

In the treatment mode, the irradiation duration is longer, in order tokeep the tumorous cell's mitochondria out of operation long enough tocause its death of the cells.

The time required for cell death is monitored by the decay of magneticechoes from tumor cells, making the dosage and duration of treatmentideal. It also serves to confirm the death of the target tumor.

When the instant invention is used to detect a virus such as Covid 19the instant invention resonates viral RNA by applying radio waves in theGHz range. Referring to FIG. 9, 910 is the E protein, 915 is the Sprotein and 920 is the M protein.

According to a study published in 2015 in the journal Nature, it istechnically possible to resonate with viral RNA by applying radio wavesin the GHz range. The Nature study experiences the fracture of the H3N2and H1N1 viruses caused by the incidence of radio waves, causing theopposite displacement between the core and shell regions of the viralnanosphere, thus generating its disruption and inactivation of thevirus.

Knowing that viruses are inert molecular structures, in general, with asize of around 500 nm, the resonance in the fundamental frequency ofmost viruses would be around 599 THz. In the special case of theSars-Cov-2 Virus with a size in the range of 325.8 nm, the fundamentalfrequency of oscillation is approximately 920 THz.

As explained previously, the electronics capable of generating signalsin the range of hundreds of THz is currently restricted in thelaboratory environment and is still being studied. Thus, theinvestigators decided to use a harmonic resonant of the fundamentalfrequency of the Sars-Cov-2 virus with ‘n’=500000. This gives us acentral frequency of 1,850,000,000 Hz.

Laboratory tests were carried out and energy absorption was perceived inthis frequency range. From this confirmation we started to analyze themagnetization and demagnetization times of the sample that resulted insmall electrical echoes of energy. This result translates into a phasevariation between the signal generated by the transmitter and the signalcaptured by the receiving antenna, as explained earlier.

The instant invention resulting from the research is a light andportable device developed for in-vitro analysis to detect among otherdiseases, the presence of the Sars-Cov-2 virus in saliva samples in afast fashion (less than 10 seconds), dispensing the need for reagents.Because it does not use reagents, it can be rapidly deployed and at alow cost be used to test multiple samples which makes it ideal for masstesting programs.

The instant invention performs quick and precise tests in saliva samplesto detect the Sars-Cov-2. The sample to be analyzed is crossed withradio waves at one of the harmonic frequencies that resonate with thevirus structure. When it resonates, it absorbs energy and it is detectedwithin a set of antennas especially calibrated to measure the energyemitted versus the energy absorbed. When there's a difference betweenboth measurements, there's a positive detection for Covid19. Thisprocess, explained in more detail previously takes no more than 10seconds.

The optimized device is shown in FIG. 10 and FIG. 11 provides anexploded view of the device.

The components that make up the system are shown in the tables below:

Item Quantity Part

TABLE 1 1 1 Cylindrical base 2 1 Shielding tube 4 1 Falcon tube 5 1Shielding lid 6 1 Top cover 6.1 1 Secondary board A, Metal sheet (touchsensor) 6.2 1 Secondary board B, Bluetooth, WIFI 802.11b/g/n, Bluetoothv4.2 + EDR, Class 1, 2 and 3 Transceiver Module 2.4 GHz~2.5GH-SURFACEMOUNT 7 1 Main boardThe Main Board is comprised of the following components:

TABLE 2 Item Quantity Part 1 1 Battery holder CR2032 2 1 BMT 1205XH9.5 31 Ceramic Capacitors 4 1 Crystal 250 MHZ @30 PPM 5 1 ADS122CD41PWP 7 2Diode array BAS40-04-7-F 8 1 Sensor AT42QT1010-TSHR 9 1 DC/DC LinearRegulator AP7361C-33SPR-13 10 1 RTC Epson SOP14 COM Cristal 11 1Bluetooth WIFI Module E5P32-WROOM-32D 12 1 EthernetControllerENC28J60-I/SO 13 1 Temperature and Moisture sensor S17021 14 1Intelligent Control LED WS2812-2020 15 1 Watchdog Timer MAX6369KA 16 1RF/IF gain and phase detector AD8302ARUZ 17 1 Flash Memory ATAES132A 181 RF LOW PASS FILTER M24C32-WMN6TP 19 1 RF LOW PASS FILTERDEA163800LT/LPF1608LL53R240A 20 1 CRYSTAL OSCILATOR TXETBDSANF 21 1 WIDEBAND SYNTHESIZER ADF4351BCPZ 22 1 RJ45 JACK JOO18D21E 23 1 INDUCTOR 1uH24 7 1.5 Ohms @100 mhZ SIGNAL LINE FERRITE BEAD BLM18HE152SN1D 25 1251NDUCTOR 5.6nH 26 1 251NDUCTOR 15nH 27 1 251NDUCTOR 7.5nH 28 1 LEDYELLOW 29 1 Micro USB 10118192-0002lf 30 1 LED RED 31 17 RESISTOR ¼ W 1%2.32K 32 1 RF SHIELD BMI-S-103 33 1 BALUN 1:1-5 TO 3000 MHz 34 1 USBRECEPTICAL, TYPE A 35 1 SMA CONNECTOR STR 50 OHM PCB 36 1 POWERAMPLIFIER HMC453ST89

In order to determine the sensitivity and specificity of the instantinvention on diagnosing Covid19 from a saliva sample, the instantinvention was used together with positive and negative control samples.These samples came from hospitals and point of care facilities locatedin the state of Espirito Santo, Brazil. As detailed in the trials flowbelow, those samples were inserted into the instant invention in orderto collect the absorption and phase for each frequency in the widespectrum of frequency from 1.4 GHz to 1.9 GHz. The first step is tocollect and analyze a reference biological sample that does not have thevirus or other pathogen or disease of interest. This becomes thestandard for the testing of samples that are suspected of containing avirus or other pathogen or disease of interest. This reference samplecan then be stored and used as a comparison in future test. As explainedin more detail previously, after running more than 1000 samples, thedata was processed and we were able to identify a high accuracy asexplained below. The trial flow chart is shown in FIG. 12. The trialutilized 1357 samples and representative results are shown below.

Instant Sample Standard invention 1 − − 2 − − 3 + + 4 + + 5 + + 6 − − 7− − 8 − − 9 + + 10 − − 11 − − 12 − − 13 − − 14 − − 15 − − 16 − − 17 + +A plus symbol indicates positive result and a negative symbol indicatesa negative result. The standard test was a PCR test (Polymerase chainreaction).

The results for the complete test can be found in the following tableand in FIG. 17:

Instant Instant invention invention POSITIVE NEGATIVE TOTAL PCR Positive490 3 493 PCR Negative 0 864 864 Total 490 867 1357

The covid 19 test results resulted in a Sensitivity: Positiveconcordance rate: 490/493 (98.98%) Specificity: Negative concordancerate: 864/864 (100%) Total concordance rate: 1354/1357 (99.77%)

Referring now to the drawings, and more particularly to FIG. 4, it showsa simple depiction of the sample 401 in test tube 400 and thetransmitter 410 and receiver 420 of the instant invention.

FIG. 5 is a flow chart of algorithm to find the best channel. Raw datafrom the instant invention at step 505 is passed to step 510 finding thebest channels and step 520 filtering raw data given the best channelwhich passes the data to step 515 subset from raw data. The system thenuses a machine learning algorithm step 525 and compares it to themachine learning model 535. The operator then reviews the data and thenit passes to diagnostic output step 540.

FIG. 6 shows a table showing the count of live cells per Elisa plate inthe control sample.

FIG. 7 shows a table of the count of live cells per Elisa well in thesample containing cancer cells.

FIG. 8 is showing a table of the surviving cancer cells compared tocontrol sample.

FIG. 9 is a model of the COVID-19 virus. Item 910 represents a typical Eprotein; item 915 represents a typical S protein; and item 920represents a typical M protein.

FIG. 10 shows the assembled view of the instant invention.

FIG. 11 shows an exploded view of the instant invention.

Item Quantity Part 1 1 Cylindrical base 2 1 Shielding tube 4 1 Falcontube 5 1 Shielding lid 6 1 Top cover 6.1 1 Secondary board A, Metalsheet (touch sensor) 6.2 1 Secondary board B, Bluetooth, WIFI802.11b/g/n, Bluetooth v4.2+ EDR, Class 1, 2 and 3 Transceiver Module2.4 GHz~2.5 GH-SURFACE MOUNT 7 1 Main board

FIG. 12 shows a flow chart of the trial process. Step 1210 is to collectthe sample and place it is test tube 1215. Step 1230 is bar code readingand the bar code on test tube 1215 or another suitable container is readby barcode scanner 1235. The sample is processed in system 1240 and thesystem results 1245 are passed to the cloud 1260. The sample is thenpassed to the PCR testing apparatus 1250 and tested in PCR testingapparatus provides results 1255. Results 1255 are passed to the PCRdatabase 1275. The PCR results 1255 are compared to the system resultsstored in the cloud 1260 at step 1270 and an analysis report is producedat step 1265. The report is reviewed by the lab personnel at step 1220and the final report is released in step 1225. The process is continueduntil all the samples are processed.

FIG. 13 shows a setup containing antenna 1310 and Elisa plates 1320inside the dipole antenna.

FIG. 14 shows a close up view of an Elisa plate 1320 proximal to theantenna 1310 and Elisa plates 1320. The right side is the negativecontrol sample.

FIG. 15 shows an irradiation sample and the formation of bubbles 1500 inthe control samples in Elisa's plate 1320.

FIG. 16 shows an irradiation sample and the formation of bubbles 1500 incancerous samples in Elisa's plate 1320.

FIG. 17 shows results for the complete Covid-19 test.

The system can be modified such that the energy absorption of thereference biological sample in a container is a stored value which isbased on historical information.

In some embodiments, the system, method or methods described above maybe executed or carried out by a computing system including a tangiblecomputer-readable storage medium, also described herein as a storagemachine, that holds machine-readable instructions executable by a logicmachine such as a processor or programmable control device to provide,implement, perform, and/or enact the above described methods, processesand/or tasks. When such methods and processes are implemented, the stateof the storage machine may be changed to hold different data. Forexample, the storage machine may include memory devices such as varioushard disk drives, CD, flash drives, cloud storage, or DVD devices. Thelogic machine may execute machine-readable instructions via one or morephysical information and/or logic processing devices. For example, thelogic machine may be configured to execute instructions to perform tasksfor a computer program. The logic machine may include one or moreprocessors to execute the machine-readable instructions. The computingsystem may include a display subsystem to display a graphical userinterface (GUI) or any visual element of the methods or processesdescribed above. For example, the display subsystem, storage machine,and logic machine may be integrated such that the above method may beexecuted while visual elements of the disclosed system and/or method aredisplayed on a display screen for user consumption. The computing systemmay include an input subsystem that receives user input. The inputsubsystem may be configured to connect to and receive input from devicessuch as a mouse, game controllers, video camera, camera, keyboard orgaming controller. For example, a user input may indicate a request thatcertain task is to be executed by the computing system, such asrequesting the computing system to display any of the above describedinformation, or requesting that the user input updates or modifiesexisting stored information for processing. A communication subsystemmay allow the methods described above to be executed or provided over acomputer network. For example, the communication subsystem may beconfigured to enable the computing system to communicate with aplurality of personal computing devices. The communication subsystem mayinclude wired and/or wireless communication devices to facilitatenetworked communication. The described methods or processes may beexecuted, provided, or implemented for a user or one or more computingdevices via a computer-program product such as via an applicationprogramming interface (API).

Since many modifications, variations, and changes in detail can be madeto the described embodiments of the invention, it is intended that allmatters in the foregoing description and shown in the accompanyingdrawings be interpreted as illustrative and not in a limiting sense.Furthermore, it is understood that any of the features presented in theembodiments may be integrated into any of the other embodiments unlessexplicitly stated otherwise. The scope of the invention should bedetermined by the appended claims and their legal equivalents.

In addition, the present invention has been described with reference toembodiments, it should be noted and understood that variousmodifications and variations can be crafted by those skilled in the artwithout departing from the scope and spirit of the invention.Accordingly, the foregoing disclosure should be interpreted asillustrative only and is not to be interpreted in a limiting sense.Further it is intended that any other embodiments of the presentinvention that result from any changes in application or method of useor operation, method of manufacture, shape, size, or materials which arenot specified within the detailed written description or illustrationscontained herein are considered within the scope of the presentinvention.

Insofar as the description above and the accompanying drawings discloseany additional subject matter that is not within the scope of the claimsbelow, the inventions are not dedicated to the public and the right tofile one or more applications to claim such additional inventions isreserved.

Although very narrow claims are presented herein, it should berecognized that the scope of this invention is much broader thanpresented by the claim. It is intended that broader claims will besubmitted in an application that claims the benefit of priority fromthis application.

While this invention has been described with respect to at least oneembodiment, the present invention can be further modified within thespirit and scope of this disclosure. This application is thereforeintended to cover any variations, uses, or adaptations of the inventionusing its general principles. Further, this application is intended tocover such departures from the present disclosure as come within knownor customary practice in the art to which this invention pertains andwhich fall within the limits of the appended claims.

What is claimed is:
 1. A method of analyzing a suspected biologicalsample to determine the frequency to identify a virus in said suspectedbiological sample comprising of: a. collecting a reference biologicalsample that does not have the virus and placing it in a first container;b. collecting said suspected biological sample and placing saidsuspected biological sample in a second container; c. exposing saidreference biological sample in said first container to radio waves; d.said radio waves having a radio wave frequency; e. exposing saidsuspected biological sample in said second container to radio wavefrequency; f. measuring the energy absorption of said radio wavefrequency of said suspected biological sample in said second container;g. measuring the phase of said reference biological sample in said firstcontainer; h. measuring the magnetic reluctance of said referencebiological sample in said first container; i. using said radio wavefrequency of said suspected biological sample in said second containerand said phase of said reference biological sample and said magneticreluctance of said reference biological sample in said first container;and j. determining the fundamental frequency.
 2. The method of analyzingsaid suspected biological sample of claim 1 wherein the virus isselected from the group consisting of Influenza, Coronavirus,Sars-Cov-2, HIV, Herpes, Dengue and Zika.
 3. The method of analyzingsaid suspected biological sample of claim 1 wherein said radio wavesfrequency is selected from the group consisting of 1500 Terahertz (THz)to 150 THz.
 4. The method of analyzing said suspected biological sampleof claim 1 wherein said radio waves frequency is preferably 920 THz. 5.The method of analyzing said suspected biological sample of claim 1wherein said radio waves frequency is a fundamental frequency toresonate with the structure.
 6. The method of analyzing said suspectedbiological sample of claim 1 wherein said energy absorption of saidreference biological sample in said container is a stored value.